Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02972684
Other study ID # RC16_0009
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 3, 2017
Est. completion date February 2020

Study information

Verified date February 2020
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac surgical interventions.

Treatment of such complication often necessitates various combinations therapeutic intervention including allogenic blood products administration, drug use and/or surgical intervention. All are expensive treatment and decision making is guided by patient clinical status and biological tests of the haemostatic function.

A key point is the time frame of the clinical process. Therapeutic choices have to be done as fast as possible to minimize bleeding consequences on patient haemodynamic and physiological status. Conventional coagulation test results availability time usually exceed 45' after blood drawing. In such situation, the results may not reflect precisely the coagulation system current state. This downside is often counterbalanced by clinicians empirical choices preceding lab test results knowledge that may conduct to inappropriate treatment, blood product overuse and undue expense.

Viscoelastic point of care test may compensate for the limitations of conventional coagulation tests. In perioperative haemorrhage, faster and more precise information about haemostatic function may help for more accurate therapeutic choices.

The IMOTEC study aims to compare haemorrhage management following cardiac surgery using conventional blood coagulation tests or thrombo-elastogaphic point of care test.

Primary endpoint is a cost utility analysis of the technology and secondary endpoints include blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative infection (any cause), organ failure, in hospital length of stay and death.


Description:

The research is a real life, prospective, single blinded stepped wedge randomized study.

Inclusion after informed consent of adult patient having cardio-vascular surgical procedure using cardiopulmonary bypass and meeting inclusion criterion "bleeding".

After meeting inclusion criterion patients are managed either using conventional blood coagulation tests or using thrombo-elastometry POC test and predefined therapeutic interventions described in a specific algorithm.

Other elements of patient clinical management follow usual center standard care .

Follow up of EQ-5D and clinical evaluations are performed at one , 6 and 12 months after inclusion.


Recruitment information / eligibility

Status Completed
Enrollment 1098
Est. completion date February 2020
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Pre-Inclusion Criteria:

- Adult patients over 18 years old scheduled for elective or urgent cardiac surgery using cardiopulmonary bypass .

- Patient informed written consent (non-opposition to data use) or person of trust or family member information .

Inclusion Criteria:

Blood Coagulation test sampling indication for intra or post-operative bleeding defined as follow:

1. intra-operative post CPB bleeding; evaluation more than 10min after heparin reversal by protamin.

- Clinically significant bleeding judged on surgeon and anesthesiologist consensual point of view

- Sternal closure delay

- Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h)

2. Postoperative period , evaluation in post operative care environment after 30min stabilization period

- Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h)

- Patient requiring surgical re-exploration for diagnosed or suspected pericardial effusion or surgical site bleeding requiring surgical hemostatic intervention

Exclusion Criteria:

- Known congenital bleeding disorder

- Redo surgery for patient previously included in the study

- Implantation of Cardiac support device, Extra Corporeal Membrane Oxygenation (ECMO) Extra Corporeal Life support (ECLS), uni or bi-ventricular artificial hearts.

- Indication for post-CPB ECMO or ECLS

- blood transfusion refusal

- pregnant women

- patients under 18 years old

- Adult patient under guardianship, trusteeship or safeguard justice

Study Design


Intervention

Device:
Thrombo-elastometry POC testing
Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage

Locations

Country Name City State
France Angers University Hospital Angers
France Bordeaux University hospital Bordeaux
France Caen University Hospital Caen
France Clermont-Ferrand University Hospital Clermont-Ferrand
France Dijon University Hospital Dijon
France Lille University hospital Lille
France Marseille AP-HM La Timone Marseille
France Nancy University Hospital Nancy
France APHP, La Pitié Salpétrière Paris
France HEGP, Hôpital Européen Georges Pompidou Paris
France Rouen University Hospital Rouen
France Saint-Etienne University Hospital Saint-Etienne
France Strasbourg Universtiy Hospital Strasbourg
France Toulouse University Hospital Toulouse
France Tours University Hospital Tours

Sponsors (2)

Lead Sponsor Collaborator
Nantes University Hospital Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (1)

Rigal JC, Boissier E, Lakhal K, Riche VP, Durand-Zaleski I, Rozec B. Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study). BMJ Open. 2019 Nov 5;9(11):e029751. doi: 10.1136/bmjopen-2019-029751. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cost-utility ratio incremental cost per incremental life year and incremental costs per incremental QALY one year
Secondary incremental cost effectiveness ratio incremental cost effectiveness ratio : difference in costs divided by the difference in mortality and serious adverse events one year
Secondary Complication rates Parameters followed during hospitalization are: volume of postoperative bleeding, allogeneic blood product transfusion, blood cell count, postoperative complications: surgical reexploration, acute kidney injury, need for renal replacement therapy, organ failure, acquired infections, mechanical ventilation duration, intensive care, and in hospital length of stay, death. one year
Secondary Complication rates The major complications that can occur within 12 months are: death, cardio-thoracic surgical intervention, acute kidney injury, need for renal replacement therapy, any serious illness diagnosis. one year
Secondary Evaluation survey Evaluation survey regarding the context and the parameters that impacted the physician's decision, which will be used a sub-group of 100 patients. Day 1
Secondary The location of the Thrombo-elastometry POC testing The location of the Thrombo-elastometry POC testing (operative room or laboratory) three years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005319 - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00000581 - Granulocyte Transfusion Study Phase 3
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Completed NCT02968654 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Enrolling by invitation NCT06019364 - Transfusion of Whole Blood in Acute Bleeding
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Completed NCT03727230 - RhD+ Blood Transfusion to Asian-type DEL Recipients N/A
Recruiting NCT06102590 - Oxygen Extraction-guided Transfusion N/A
Completed NCT00400192 - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury N/A
Completed NCT00000593 - Viral Activation Transfusion Study (VATS) N/A
Completed NCT05581238 - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Completed NCT05627544 - Blood Transfusion Applications in Hip Replacements
Not yet recruiting NCT03429790 - Cell Salvage During Caesarean Section (CSCS) N/A
Completed NCT00822588 - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not N/A
Withdrawn NCT00269971 - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. Phase 3